Synta Pharmaceuticals Director Buys 756K Shares and 3 Insider Buys to Note

Kovner, Bruce, who is Director at Synta Pharmaceuticals Corp. (NASDAQ:SNTA), bought 756,000 shares at $4.71 per share for a total value of $3,561,743. The shares recently traded at $4.34, down $0.37, or 7.86% since the insider buy.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

SNTA

Celgene European Investment Co., which owns a 10% stake in Celgene Corporation (NASDAQ:CELG), bought 66,666 shares at $15.00 per share for a total value of $999,990. The shares recently traded at $115.56, up $100.56, or 670.4% since the insider buy.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

CELG

Calamos, John P. Sr., who is Chairman, CEO, Global Co-CIO at Calamos Asset Management Inc. (NASDAQ:CLMS), bought 58,994 shares at $10.57 per share for a total value of $623,577. The shares recently traded at $10.73, up $0.16, or 1.51% since the insider buy.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

CLMS

Baker, Felix, who is Director at Genomic Health Inc. (NASDAQ:GHDX), bought 217,773 shares at $35.82 per share for a total value of $7,799,540. The shares recently traded at $35.65, down $0.17, or 0.47% since the insider buy.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

GHDX

Investing Insights: Is Pfizer a Buy at These Prices?

More Articles About:   ,  

More from The Cheat Sheet